CRISPR gene editing is a promising therapy for treating rare genetic diseases. Delivering this therapy directly to patients is challenging because the CRISPR cargo needs protection from degradation. For this reason, most successful CRISPR clinical trials use patient-derived cells that are corrected in vitro. New approaches in nanoparticle and virus delivery methods make it possible to edit disease-causing genes directly in the body. In this webinar, researchers will discuss in vivo gene editing advancements that open the door for treating a wide range of genetic disorders.
Topics to be covered • CRISPR-Cas9 delivery vehicles for in vivo editing
• How to minimize off-target CRISPR-induced mutations
• Ameliorating behavior deficits in Fragile X syndrome
Education & learning
ADDITIONAL INFO
Categories:
Education & learning
When:
Monday, October 25, 2021 · 1:00 p.m.
Eastern Time (US & Canada)
Duration: 1 hour 30 minutes
Price:Free
Language:English
Who can attend?Anyone with the event link can attend
Dial-in available?
(listen only):Yes.
Dial-in Number:
Please register for this Webinar to view the dial-in info.
Professor, Department of Bioengineering, University of California, Berkeley
Niren Murthy is a professor in the Department of Bioengineering at the University of California, Berkeley. In 2001, Murthy received his PhD from the University of Washington in bioengineering and then did postdoctoral research at UC Berkeley in...
Assistant Professor, Department of Cellular and Integrative Physiology, The University of Texas, Health Science Center at San Antonio
Hye Young Lee is an assistant professor in the Department of Cellular and Integrative Physiology at The University of Texas, Health Science Center at San Antonio. Lee received her PhD in Life Sciences at the Pohang University of Science and...